Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
✍ Scribed by Hézode, Christophe (author);Hirschfield, Gideon M. (author);Ghesquiere, Wayne (author);Sievert, William (author);Rodriguez-Torres, Maribel (author);Shafran, Stephen D. (author);Thuluvath, Paul J. (author);Tatum, Harvey A. (author);Waked, Imam (author);Esmat, Gamal (author);Lawitz, Eric J. (author);Rustgi, Vinod K. (author);Pol, Stanislas (author);Weis, Nina (author);Pockros, Paul J. (author);Bourlière, Marc (author);Serfaty, Lawrence (author);Vierling, John M. (author);Fried, Michael W. (author);Weiland, Ola (author);Brunetto, Maurizia R. (author);Everson, Gregory T. (author);Zeuzem, Stefan (author);Kwo, Paul Y. (author);Sulkowski, Mark (author);Bräu, Norbert (author);Hernandez, Dennis (author);McPhee, Fiona (author);Wind-Rotolo, Megan (author);Liu, Zhaohui (author);Noviello, Stephanie (author);Hughes, Eric A. (author);Yin, Philip D. (author);Schnittman, Steven (author)
- Book ID
- 125834869
- Publisher
- BMJ Publishing Group
- Year
- 2014
- Tongue
- English
- Weight
- 710 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0017-5749
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12